GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Everest Medicines Ltd (HKSE:01952) » Definitions » Scaled Net Operating Assets

Everest Medicines (HKSE:01952) Scaled Net Operating Assets : 0.58 (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Everest Medicines Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Everest Medicines's operating assets for the quarter that ended in Dec. 2024 was HK$3,582.6 Mil. Everest Medicines's operating liabilities for the quarter that ended in Dec. 2024 was HK$331.5 Mil. Everest Medicines's Total Assets for the quarter that ended in Jun. 2024 was HK$5,573.6 Mil. Therefore, Everest Medicines's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2024 was 0.58.


Everest Medicines Scaled Net Operating Assets Historical Data

The historical data trend for Everest Medicines's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Everest Medicines Scaled Net Operating Assets Chart

Everest Medicines Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Scaled Net Operating Assets
Get a 7-Day Free Trial 1.40 0.52 0.62 0.46 0.52

Everest Medicines Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.73 0.47 0.53 0.52 0.58

Competitive Comparison of Everest Medicines's Scaled Net Operating Assets

For the Biotechnology subindustry, Everest Medicines's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Everest Medicines's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Everest Medicines's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Everest Medicines's Scaled Net Operating Assets falls into.


;
;

Everest Medicines Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Everest Medicines's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2024 )
=(Operating Assets (A: Dec. 2024 )-Operating Liabilities (A: Dec. 2024 ))/Total Assets (A: Dec. 2023 )
=(3582.616-331.456)/6314.136
=0.51

where

Operating Assets(A: Dec. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=5294.423 - 1711.807
=3582.616

Operating Liabilities(A: Dec. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=946.015 - 92.479 - 522.08
=331.456

Everest Medicines's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Dec. 2024 )
=(Operating Assets (Q: Dec. 2024 )-Operating Liabilities (Q: Dec. 2024 ))/Total Assets (Q: Jun. 2024 )
=(3582.616-331.456)/5573.648
=0.58

where

Operating Assets(Q: Dec. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=5294.423 - 1711.807
=3582.616

Operating Liabilities(Q: Dec. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=946.015 - 92.479 - 522.08
=331.456

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Everest Medicines Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Everest Medicines's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Everest Medicines Business Description

Traded in Other Exchanges
Address
1168 West Nanjing Road, 16th Floor, CITIC Pacific Plaza, Jing’an District, Shanghai, CHN, 200041
Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes; Nefecon (TarpeyoTM), EVER001 (previously known as XNW1011), PTX-COVID19-B, Eravacycline (Xerava), EVER206 (also known as SPR206), and others.
Executives
Fu Wei 2307 Founder of a discretionary trust who can infl
Nova Aqua Limited 2201 Interest of corporation controlled by you
C-bridge Capital Gp Iv, Ltd. 2201 Interest of corporation controlled by you
C-bridge Healthcare Fund Gp Iv, L.p. 2201 Interest of corporation controlled by you
C-bridge Healthcare Fund Iv, L.p. 2201 Interest of corporation controlled by you
Tf Capital Iv Ltd. 2201 Interest of corporation controlled by you
C-bridge Capital Gp, Ltd. 2501 Other
C-bridge Healthcare Fund Gp Ii, L.p. 2501 Other
C-bridge Healthcare Fund Ii, L.p. 2501 Other
C-bridge Investment Everest Limited 2501 Other
Tf Capital Ii Ltd. 2501 Other
Everest Management Holding Co., Ltd. 2101 Beneficial owner
Fu Wei 2307 Founder of a discretionary trust who can infl
C-bridge Joint Value Creation Limited 2201 Interest of corporation controlled by you
Kolchinsky Anna Inge Leonore Haas 2202 Interest of your spouse

Everest Medicines Headlines

No Headlines